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To the editor:
Screening for c-mpl mutations in patients with congenital amegakaryocytic thrombocytopenia identifies a polymorphism
Congenital amegakaryocytic thrombocytopenia (CAMT) is an uncommon disorder, characterized by an isolated thrombocytopenia and the almost complete absence of megakaryocytes in the bone marrow. Several studies have indicated that the origin of CAMT is an intrinsic stem cell defect. [1] [2] [3] Recently, we and others have demonstrated the presence of mutations in the thrombopoietinreceptor gene, c-mpl, as a possible cause of CAMT. [4] [5] [6] [7] Although some mutations directly predict loss of Mpl function, it has not been established that others, notably those that lead to an amino acid substitution, also directly predict this loss.
To exclude that the mutations we found in our patients represent non-disease-related polymorphisms, we screened 50 healthy donors (100 alleles) for the presence of the different mutations by either sequence analysis or allele-specific restriction analysis. 4 None of the healthy donors were carriers of our reported CAMTassociated mutations. In one new CAMT patient, 3 heterozygous mutations were observed: a G-to-C substitution at nucleotide 305 in exon 3, predicting an arginine-to-proline substitution at codon 102; a G-to-A transition at position 340, also in exon 3, leading to valine-to-methionine replacement at codon 114 (Mpl-114V/M); and a G-to-C substitution in the fifth nucleotide of intron 3, which leads to loss of the splice site 3Ј of exon 3. Screening of 50 healthy donors revealed that 4 were heterozygous carriers of the G340A mutation. The other mutations were not observed in this population. The c-mpl-340A gene thus seems to have a frequency of 0.04 in a white Dutch population. Functional studies should reveal whether this Mpl-114V/M polymorphism influences the function of Mpl.
Recently, Ballmaier et al 7 reported c-mpl mutations in another series of patients with CAMT. One of their patients was a homozygous carrier for 2 different point mutations. One mutation predicted a stopcodon in exon 3. The second mutation was the G340A mutation, which we also found in healthy donors. Therefore, we propose that the first mutation plays a role in the development of CAMT in this patient. The G340A may not be involved in CAMT, and its presence in 2 CAMT patients may be incidental.
In conclusion, mutations that predict amino-acid substitutions found by genetic screening of patients with CAMT can be due to polymorphisms of the c-mpl gene. The relation of such mutations to disease should be proven by functional studies with the mutated protein.
